OLIARO BOSSO, Simonetta
OLIARO BOSSO, Simonetta
SCIENZA E TECNOLOGIA DEL FARMACO
4-methyl zymosterone and other 4-methyl intermediates of sterol biosynthesis from yeast mutants engineered in the ERG27 gene encoding 3-ketosteroid reductase
2015-01-01 Ferrante, Terenzio; Barge, Alessandro; Albezzano, Claudia; Ballestrazzi Clara; Balliano, Gianni; Oliaro-Bosso, Simonetta
4-Methylzymosterone and Other Intermediates of Sterol Biosynthesis from Yeast Mutants Engineered in the ERG27 Gene Encoding 3-Ketosteroid Reductase
2016-01-01 Ferrante, T; Barge, A; Taramino, S; Oliaro-Bosso, S; Balliano, G
A mutation in yeast oxidosqualene cyclase (Erg7) makes it independent of 3-ketoreductase activity (Erg27)
2012-01-01 Layer Jacob V; Barnes Brett M; Yamasaki Yuji; Barbuch Robert; Li Lingtao; Taramino Silvia; Oliaro-Bosso Simonetta; Balliano Gianni; Bard Martin
A new bevacizumab carrier for intravitreal administration: Focus on stability
2021-01-01 Chirio D.; Peira E.; Sapino S.; Chindamo G.; Oliaro-bosso S.; Adinolfi S.; Dianzani C.; Baratta F.; Gallarate M.
Access of the substrate to the active site of squalene and oxidosqualene cyclases: comparative inhibition, site-directed mutagenesis and homology-modelling studies.
2005-01-01 S. OLIARO-BOSSO; T. SCHULZ-GASCH; S. TARAMINO; M. SCALDAFERRI; F. VIOLA; G. BALLIANO
Access of the substrate to the active site of yeast oxidosqualene cyclase: a modelling and site-directed mutagenesis approach
2009-01-01 S. Oliaro-Bosso; S. Taramino; Y. Ferrari; G. Ermondi; G. Caron; F. Viola; G. Balliano
Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis appoach.
2004-01-01 OLIARO-BOSSO S.; SCALDAFERRI M.; TARAMINO S.; F. VIOLA; G. BALLIANO
Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach.
2005-01-01 Balliano G.; Oliaro-Bosso S.; Taramino S.; Viola F
Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach.
2005-01-01 S. OLIARO-BOSSO; T. SCHULZ-GASCH; G. BALLIANO; F. VIOLA.
AKR1C3 is a biomarker and druggable target for oropharyngeal tumors
2021-01-01 Peraldo-Neia C.; Ostano P.; Mello-Grand M.; Guana F.; Gregnanin I.; Boschi D.; Oliaro-Bosso S.; Pippione A.C.; Carenzo A.; De Cecco L.; Cavalieri S.; Micali A.; Perrone F.; Averono G.; Bagnasacco P.; Dosdegani R.; Masini L.; Krengli M.; Aluffi-Valletti P.; Valente G.; Chiorino G.
Aminopropylindenes derived from Grundmann’s ketone as a novel chemotype of oxidosqualene cyclase inhibitors.
2013-01-01 S. Lange; M. Keller; C. Müller; S. Oliaro-Bosso;G. Balliano; F. Bracher
Analogs of squalene and oxidosqualene inhibit oxidosqualene cyclase of Trypanosoma cruzi expressed in Saccharomyces cerevisiae
2005-01-01 Oliaro Bosso S.; Ceruti M.; Balliano G.; Milla P.; Rocco F.; Viola F.
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention
2017-01-01 Pippione, Agnese C.; Boschi, Donatella; Pors, Klaus; Oliaro-Bosso, Simonetta; Lolli, Marco L.
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3)
2019-01-01 Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3)
2019-01-01 Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro Bosso, Marco Lucio Lolli, Donatella Boschi
Arylpiperidines as a new class of oxidosqualene cyclase inhibitors
2016-01-01 Keller, M.; Wolfgardt, A.; Müller, C.; Wilcken, R.; Böckler, F.M.; Oliaro-Bosso, S.; Ferrante, T.; Balliano, G.; Bracher, F.
Assessment of in‐situ gelling microemulsion systems upon temperature and dilution condition for corneal delivery of bevacizumab
2021-01-01 Peira E.; Chindamo G.; Chirio D.; Sapino S.; Oliaro-bosso S.; Rebba E.; Ivanchenko P.; Gallarate M.
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3
2019-01-01 Lolli, Marco L; Carnovale, Irene M; Pippione, Agnese C; Wahlgren, Weixiao Y; Bonanni, Davide; Marini, Elisabetta; Zonari, Daniele; Gallicchio, Margherita; Boscaro, Valentina; Goyal, Parveen; Friemann, Rosmarie; Rolando, Barbara; Bagnati, Renzo; Adinolfi, Salvatore; Oliaro-Bosso, Simonetta; Boschi, Donatella
Cannabinoid Delivery Systems for Pain and Inflammation Treatment
2018-01-01 Bruni, Natascia; Della Pepa, Carlo; Oliaro-Bosso, Simonetta; Pessione, Enrica; Gastaldi, Daniela; Dosio, Franco
Characterization of the Channel Constriction Allowingthe Access of the Substrate to the Active Site of YeastOxidosqualene Cyclase
2011-01-01 Simonetta Oliaro-Bosso; Giulia Caron; Silvia Taramino; Giuseppe Ermondi; Franca Viola; Gianni Balliano
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 4-methyl zymosterone and other 4-methyl intermediates of sterol biosynthesis from yeast mutants engineered in the ERG27 gene encoding 3-ketosteroid reductase | 2015 | Ferrante, Terenzio; Barge, Alessandro; Albezzano, Claudia; Ballestrazzi Clara; Balliano, Gianni; Oliaro-Bosso, Simonetta | |
| 4-Methylzymosterone and Other Intermediates of Sterol Biosynthesis from Yeast Mutants Engineered in the ERG27 Gene Encoding 3-Ketosteroid Reductase | 2016 | Ferrante, T; Barge, A; Taramino, S; Oliaro-Bosso, S; Balliano, G | |
| A mutation in yeast oxidosqualene cyclase (Erg7) makes it independent of 3-ketoreductase activity (Erg27) | 2012 | Layer Jacob V; Barnes Brett M; Yamasaki Yuji; Barbuch Robert; Li Lingtao; Taramino Silvia; Oliaro-Bosso Simonetta; Balliano Gianni; Bard Martin | |
| A new bevacizumab carrier for intravitreal administration: Focus on stability | 2021 | Chirio D.; Peira E.; Sapino S.; Chindamo G.; Oliaro-bosso S.; Adinolfi S.; Dianzani C.; Baratta F.; Gallarate M. | |
| Access of the substrate to the active site of squalene and oxidosqualene cyclases: comparative inhibition, site-directed mutagenesis and homology-modelling studies. | 2005 | S. OLIARO-BOSSO; T. SCHULZ-GASCH; S. TARAMINO; M. SCALDAFERRI; F. VIOLA; G. BALLIANO | |
| Access of the substrate to the active site of yeast oxidosqualene cyclase: a modelling and site-directed mutagenesis approach | 2009 | S. Oliaro-Bosso; S. Taramino; Y. Ferrari; G. Ermondi; G. Caron; F. Viola; G. Balliano | |
| Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis appoach. | 2004 | OLIARO-BOSSO S.; SCALDAFERRI M.; TARAMINO S.; F. VIOLA; G. BALLIANO | |
| Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach. | 2005 | Balliano G.; Oliaro-Bosso S.; Taramino S.; Viola F | |
| Access of the substrate to the active site of yeast oxidosqualene cyclase: an inhibition and site-directed mutagenesis approach. | 2005 | S. OLIARO-BOSSO; T. SCHULZ-GASCH; G. BALLIANO; F. VIOLA. | |
| AKR1C3 is a biomarker and druggable target for oropharyngeal tumors | 2021 | Peraldo-Neia C.; Ostano P.; Mello-Grand M.; Guana F.; Gregnanin I.; Boschi D.; Oliaro-Bosso S.; Pippione A.C.; Carenzo A.; De Cecco L.; Cavalieri S.; Micali A.; Perrone F.; Averono G.; Bagnasacco P.; Dosdegani R.; Masini L.; Krengli M.; Aluffi-Valletti P.; Valente G.; Chiorino G. | |
| Aminopropylindenes derived from Grundmann’s ketone as a novel chemotype of oxidosqualene cyclase inhibitors. | 2013 | S. Lange; M. Keller; C. Müller; S. Oliaro-Bosso;G. Balliano; F. Bracher | |
| Analogs of squalene and oxidosqualene inhibit oxidosqualene cyclase of Trypanosoma cruzi expressed in Saccharomyces cerevisiae | 2005 | Oliaro Bosso S.; Ceruti M.; Balliano G.; Milla P.; Rocco F.; Viola F. | |
| Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention | 2017 | Pippione, Agnese C.; Boschi, Donatella; Pors, Klaus; Oliaro-Bosso, Simonetta; Lolli, Marco L. | |
| Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) | 2019 | Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi | |
| Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) | 2019 | Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro Bosso, Marco Lucio Lolli, Donatella Boschi | |
| Arylpiperidines as a new class of oxidosqualene cyclase inhibitors | 2016 | Keller, M.; Wolfgardt, A.; Müller, C.; Wilcken, R.; Böckler, F.M.; Oliaro-Bosso, S.; Ferrante, T.; Balliano, G.; Bracher, F. | |
| Assessment of in‐situ gelling microemulsion systems upon temperature and dilution condition for corneal delivery of bevacizumab | 2021 | Peira E.; Chindamo G.; Chirio D.; Sapino S.; Oliaro-bosso S.; Rebba E.; Ivanchenko P.; Gallarate M. | |
| Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3 | 2019 | Lolli, Marco L; Carnovale, Irene M; Pippione, Agnese C; Wahlgren, Weixiao Y; Bonanni, Davide; Marini, Elisabetta; Zonari, Daniele; Gallicchio, Margherita; Boscaro, Valentina; Goyal, Parveen; Friemann, Rosmarie; Rolando, Barbara; Bagnati, Renzo; Adinolfi, Salvatore; Oliaro-Bosso, Simonetta; Boschi, Donatella | |
| Cannabinoid Delivery Systems for Pain and Inflammation Treatment | 2018 | Bruni, Natascia; Della Pepa, Carlo; Oliaro-Bosso, Simonetta; Pessione, Enrica; Gastaldi, Daniela; Dosio, Franco | |
| Characterization of the Channel Constriction Allowingthe Access of the Substrate to the Active Site of YeastOxidosqualene Cyclase | 2011 | Simonetta Oliaro-Bosso; Giulia Caron; Silvia Taramino; Giuseppe Ermondi; Franca Viola; Gianni Balliano |